Kyusju Tong acquires step-by-step subsidiary to undertake prescription outflow

September 21, Shandong Step Pharmaceuticals issued a progress announcement, in order to optimize the company's asset structure, Shandong Step Pharmaceutical Co., Ltd. (hereinafter referred to as "Step Pharmaceuticals") considered and passed the "Proposal on the Company's proposed transfer of the controlling subsidiary's equity", agreed to the company's controlling subsidiary Hubei Step Kyushua Pharmaceutical Co., Ltd. (hereinafter referred to as "Hubei Step Kyushuan") 51% of the shares transferred to Kyushua Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Kyushuan").In the announcement, Hubei step-by-step Kyushua Tong has completed the registration of industrial and commercial changes, and obtained the Hubei Provincial Market Supervision Bureau issued a "business license." After the completion of this industrial and commercial change, Hubei Kyushua Tong will no longer be included in the scope of the step consolidation report, which means that Kyushua Tong officially obtained control of the company of Hubei step Kyushua Tong, the transfer work is basically completed.Data show that step pharmaceutical and Kyusju Tong's cooperation, as early as 2017, the establishment of the company is located in the medical institutions pharmacy custody (drugs, supplies, Chinese medicine and other centralized distribution business).However, with the adjustment of the policy, the two changed course in time, adjust the strategy, issued a notice that: the two enterprises adjust the cooperative business model (including professional social pharmacies in the hospital, DTP pharmacies, hospital-side pharmacies, hospital-side clinics, etc.).At the same time, the announcement shows that the current pharmaceutical division, zero rate and other policies, professional pharmacies have great potential for development, determined to work together to build a professional pharmacy chain brand. Joint venture head office to create a "nine-step" big pharmacy brand, and authorized the use of chain companies around, investment in the establishment of all over the nine-step big pharmacy chain Co., Ltd.In the same year, Step Pharmaceuticals issued a more detailed strategic plan for nine-step pharmacies: Hubei step-by-step Kyushua Tong intends to invest in nine-step large pharmacies (chain) Co., Ltd. in 31 provinces across the country with other interested parties. It is estimated that 42 "nine-step pharmacies" will be invested averaging no more than 2 million yuan each, and the total investment is not expected to exceed 84 million yuan.This time, however, with Hubei step Kyushua to complete the industrial and commercial changes, step-by-step pharmaceutical completely divested the pharmacy business.

to undertake prescription outflowsData show that the "nine steps" business positioning in professional social pharmacies, DTP pharmacies, hospital side clinics, etc. , from the nearest hospital side shop cut-off from patients, perhaps to see the medical separation background, with volume procurement and prohibition of pharmacy trusteeship and other policies introduced, so that out-of-hospital channels can be faster to undertake the increase brought about by the outflow of prescriptions.To some extent, step pharmaceutical in the slow disease varieties, there are certain advantages, such as its involves in cardiovascular disease, the exclusive patented varieties of cerebrovascular capsules, steady heart particles, Danhong injections and valley red injections are commonly used drugs for patients with chronic diseases, previously decided to lay out the hospital side market, step or see the dividend of prescription exoded, want to seek new business growth points.However, Step Pharmaceuticals' 2019 report shows that during the reporting period, the company's long-term receivables amounted to 12.38 million yuan, mainly for the new investment in pharmacies by Step Kyusju Tong. The announcement made it clear that Step Kyushua Tong will not be fully operational in 2019, so Step Pharma will not make any investment in Hubei Step Kyushua Tong in 2019.Perhaps because of the policy changes, pharmacy trusteeship is banned, the drug companies this road is difficult to get through, but also because of the lack of resources and experience to operate pharmacies, pharmaceutical companies can not compete with the retail side of the powerful competitors, step-by-step pharmaceutical timely, is also wise.At the same time, Kyusju Tong to undertake the yard side shop is more logical. Data show that Kyusju Tong, as the country's largest private pharmaceutical circulation enterprises, mainly to primary medical institutions pharmacies and private hospitals as the object, to provide drug sales and distribution services, so the company has a strong logistics and distribution capacity and terminal resources.In addition, Kyusju Tong's current business scope has covered the entire pharmaceutical industry, involving pharmaceutical research and development, manufacturing, distribution and retail areas, sales terminals have covered hospitals, health stations, clinics and terminal pharmacies at all levels, and completed the construction of e-commerce platform sales channels, that is, Kyuscom's strong logistics system and terminal control, can better develop and undertake the hospital side market.

hospital side shop, a lot of pharmaceutical companies pile layoutUnder the general trend of prescription exoded, the layout of hospital side shops and primary medical drug distribution, and hospital outpatient pharmacies to form complementary varieties, has become one of the future strategies of many pharmaceutical distribution enterprises.It is understood that 75% of prescription drugs in Japan are sold in out-of-hospital markets, while 69.5% of prescriptions that flow outside the hospital are in pharmacies 500 meters near the hospital.To some extent, prescription outflow has been an irreversible trend, national supporting policies will gradually keep up, enterprises should be proactive, long-term layout, and yardside shops and DTP pharmacies will be the most able to undertake the pattern of prescription outflow. The leading enterprises of pre-layout yardside shops and DTP pharmacies have the tendency to preempt the rapid development of prescription outflow.In addition to Kyusju Tong, there are also a number of commercial companies to lay out. For example, the National University pharmacy through the hospital side shop to seize prescription outflow, as of the end of 2017, the National University pharmacy has a total of 253 stores around the hospital. In 2017, the University pharmacy added 53 stores around the hospital (28 of which have opened health insurance), of which 16 hospitals have made a cumulative profit.However, it should be noted that the pain point of prescription exoded can not be ignored, pharmacies to undertake prescriptions have a certain degree of difficulty, whether retail pharmacies have the ability to provide professional patient education and drug guidance ...In general, because retail pharmacies, batch zero integrated enterprises have long been in the front line of pharmaceutical distribution retail, has a wealth of pharmaceutical distribution and distribution, pharmaceutical services experience, the first layout, will be faster and more likely to benefit from the outflow of prescriptions. (Cypress Blue)